HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reinstated coverage on First Wave BioPharma (NASDAQ:FWBI) with a Neutral rating.
March 25, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
First Wave BioPharma has been reinstated with a Neutral rating by HC Wainwright & Co. analyst Yi Chen.
The reinstatement of coverage with a Neutral rating suggests a balanced view on the stock by the analyst. This could indicate that the analyst sees the company's prospects as neither significantly positive nor negative in the short term, leading to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100